Table 7.

Comparison of pharmacokinetic parameters between rHSA/IFNα2a 750 μg and PEG‐IFNα2a 180 μg

Group	t 1/2	T max	C max	AUC 0–t	AUC 0–∞
	h	h	pg ml −1	pg ml −1 *h	pg ml −1 *h
First dose of IFNα2a
rHSA/IFNα2a 600 μg	135.01 ± 36.47	75.00 ± 30.59	11 167.54 ± 6341.74	2 381 878.01 ± 879 806.14	2 518 504.60 ± 1 022 285.89
PEG‐IFNα2a 180 μg	58.49 ± 41.67	76.50 ± 47.97	8844.80 ± 5896.85	997 666.67 ± 582 275.47	1 096 047.58 ± 510 189.16
P‐value	<0.0001	0.16	0.23	<0.0001	<0.0001
Last dose of IFNα2a
rHSA/IFNα2a 600 μg	121.61 ± 46.76	74.00 ± 20.67	12 602.02 ± 9248.22	3 094 334.86 ± 1948 097.91	3 241 543.80 ± 2 060 188.09
PEG‐IFNα2a 180 μg	112.40 ± 29.14	69.00 ± 8.49	15 510.89 ± 4961.44	3 761 834.45 ± 707 272.76	3 938 956.18 ± 856 911.91
P‐value	0.96	0.9	0.78	0.28	0.78
First dose of neopterin
rHSA/IFNα2a 600 μg		78.00 ± 45.36	29.24 ± 7.37	10 607.02 ± 2893.85
PEG‐IFNα2a 180 μg		51.00 ± 22.90	40.70 ± 14.29	8939.34 ± 2368.70
P‐value		0.19	0.96	<0.0001
Last dose of neopterin
rHSA/IFNα2a 600 μg		68.33 ± 54.59	19.71 ± 6.71	8759.53 ± 3026.83
PEG‐IFNα2a 180 μg		87.00 ± 27.77	28.36 ± 3.96	10 348.77 ± 2107.19
P‐value		0.96	0.61	0.19

Group	CLz/F	MRT 0‐∞	Vz/F	R	Cavg	Df
	L h −1	h	L	–	pg ml −1	%
First dose of IFNα2a
rHSA/IFNα2a 600 μg	0.35 ± 0.10	255.44 ± 55.19	64.22 ± 14.26
PEG‐IFNα2a 180 μg	2.35 ± 3.92	130.80 ± 67.30	93.75 ± 98.69
P‐value	<0.0001	0.01	0.87
Last dose of IFNα2a
rHSA/IFNα2a 600 μg	2.68 ± 6.00	229.04 ± 71.46	161.24 ± 285.76	1.19 ± 0.11	7331.42 ± 4725.62	166.97 ± 96.49
PEG‐IFNα2a 180 μg	0.39 ± 0.14	207.54 ± 32.82	54.98 ± 13.46	1.55 ± 0.23	12 573.85 ± 3706.2	55.9 ± 22.61
P‐value	<0.0001	0.34	0.07	0.71	0.71	0.07

Last dose: IFNα2a serum concentration achieved a steady state after multiple doses, and the parameters were C _ssmax, AUC_ss0–t, AUC_ss0–∞, t _{ss 1/2}, T _ssmax, CLz/F_ss, MRT_ss0–∞, and Vz/F_ss, respectively.